AA
SMMT icon

ALPS Advisors’s Summit Therapeutics SMMT Stock Holding History

ALPS Advisors’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-494,924
Closed -$2.05M – 997
2024
Q1 		$2.05M Sell
494,924
-37,482
-7% -$149K 0.01% 344
2023
Q4 		$1.39M Buy
532,406
+17,471
+3% +$35.9K 0.01% 396
2023
Q3 		$963K Buy
514,935
+2,101
+0.4% +$4.01K 0.01% 463
2023
Q2 		$1.29M Buy
+512,834
New +$936K 0.01% 413

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

ALPS Advisors's SMMT Position: Q2 2024 in Review

ALPS Advisors sold out of Summit Therapeutics (SMMT) in Q2 2024, closing a stake of 494,924 shares — an estimated $2.05M sold.

ALPS Advisors first reported a position in SMMT in Q2 2023 and held it in 4 quarters. The position peaked at $2.05M in Q1 2024. 123 funds tracked by Wall St. Rank hold SMMT as of Q2 2024.

  • ALPS Advisors reported no remaining Summit Therapeutics position as of Q2 2024 after selling out during the quarter.
  • ALPS Advisors sold 494,924 Summit Therapeutics shares in Q2 2024, an estimated $2.05M.
  • ALPS Advisors first reported a position in Summit Therapeutics in Q2 2023 and held it in 4 quarters.
  • ALPS Advisors's Summit Therapeutics position peaked at $2.05M in Q1 2024.
  • 123 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2024.

Based on ALPS Advisors's 13F filing for Q2 2024, filed 13 Aug 2024.